Related references
Note: Only part of the references are listed.Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections
Richard Gale et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
Cost-Utility of Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion
James Lin et al.
OPHTHALMOLOGY RETINA (2021)
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion A Randomized Clinical Trial
Philip Hykin et al.
JAMA OPHTHALMOLOGY (2019)
Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors
Kimberly Spooner et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications Secondary Outcomes From the SCORE2 Randomized Clinical Trial
Ingrid U. Scott et al.
JAMA OPHTHALMOLOGY (2018)
Treatment of Macular Edema Due to Central Retinal Vein Occlusion Another Score for Repackaged Bevacizumab
Neil M. Bressler
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion The SCORE2 Randomized Clinical Trial
Ingrid U. Scott et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Intravitreal anti-VEGF Treatment in Central Retinal Vein Occlusion (CRVO): a Meta-Analysis of One Year Results
H. Gerding
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE (2017)
Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)
Tom Kornhauser et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2016)
Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up
Jasmina Bajric et al.
SEMINARS IN OPHTHALMOLOGY (2016)
Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18 Billion Over A Ten-Year Period
David Hutton et al.
HEALTH AFFAIRS (2014)
Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab The RETAIN Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion One-Year Results of the Phase 3 GALILEO Study
Jean-Francois Korobelnik et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study
David M. Brown et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
REPEATED INTRAVITREAL BEVACIZUMAB INJECTION WITH AND WITHOUT MACULAR GRID PHOTOCOAGULATION FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA
Kamal A. M. Solaiman et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
PROSPECTIVE STUDY OF PERIPHERAL PANRETINAL PHOTOCOAGULATION OF AREAS OF NONPERFUSION IN CENTRAL RETINAL VEIN OCCLUSION
Richard F. Spaide
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Ranibizumab for Macular Edema Due to Retinal Vein Occlusions Long-term Follow-up in the HORIZON Trial
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study
David L. J. Epstein et al.
OPHTHALMOLOGY (2012)
Benefit from Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized Study
David L. Epstein et al.
OPHTHALMOLOGY (2012)
TWO-YEAR RESULTS OF A RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS LASER IN DIABETIC MACULAR EDEMA
Masoud Soheilian et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2012)
The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package
Thunyarat Anothaisintawee et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2012)
Vitreous Levels of Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor in Macular Edema with Central Retinal Vein Occlusion
Hidetaka Noma et al.
CURRENT EYE RESEARCH (2011)
Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study
David M. Brown et al.
OPHTHALMOLOGY (2011)
Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2011)
COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION Results of the Pan American Collaborative Retina Study Group at 24 Months
Lihteh Wu et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion
John J. Wroblewski et al.
ARCHIVES OF OPHTHALMOLOGY (2009)
Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema The Pan-American Collaborative Retina Study Group at 24 Months
J. Fernando Arevalo et al.
OPHTHALMOLOGY (2009)
Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator
Peter A. Campochiaro et al.
MOLECULAR THERAPY (2008)
Share Paper
